Any current/future new fundraising through debt or equity?

The company has not explicitly mentioned any current or future fundraising plans through debt or equity in the provided transcript. However, Ashok Hiremath indicated that recent evaluations suggest the planned investment figure (capex) may go up. They are prepared to be more aggressive with investment plans in the future, which may imply potential future capital raising. Currently, the company is borrowing at very low rates (4.1%) and leveraging working capital efficiently to improve profitability. The planned capex is Rs.150 Crore for the current year and Rs.300-350 Crore over a 2-3 year wind

Any current/future capex/capital investment/strategic investment?

Capex plan for FY2022 is on track with an expected spend of Rs.150 Crore. Investments include completion of the new herbicide facility and ongoing construction of a new fungicide plant. A new state-of-the-art R&D center is under construction, expected to be completed by the end of FY2023; currently, additional R&D capacities have been hired externally. Future capex estimates over a 2-3 year window are expected to be in the Rs.300-350 Crore range, with potential to increase as per recent evaluations. The company plans to be aggressive with capital investments to expand product portfolios and ca

Future growth expectations in sales/revenue/volumes?

Astec LifeSciences expects annualized sales growth of 15%-20% for FY2022. Volume growth in H1 FY2022 was about 11%. Enterprise sales value growth is targeted at 20%-25% this year, driven by 10%-15% volume growth. CMO business is projected to grow at a compounded annual rate of 50% over the next three years. CMO contribution is expected to rise gradually, with herbicide plant ramp-up increasing CMO capacity utilization from 30% this year to higher next year. New product introductions: 4 CMO products and 1 enterprise product this year; 2 more enterprise products expected in FY2023. Full utilizat

Future growth expectations in earnings/operating earnings/profits/EPS?

Astec LifeSciences targets annualized revenue growth of 15%-20% as a general guidance. EBITDA margins expected to improve from about 22% to 24% over coming years due to higher CMO business contribution, which commands ~5% better margins than enterprise sales. The company anticipates a 50% growth in CMO business in FY2023 as new herbicide and fungicide products ramp up. Enterprise business volume growth expected at 10%-15% with 20%-25% value growth in the current year. Pricing pressures on key products are easing, with improved realizations expected, particularly in H2 FY2022. Backward integrat

Current/ Expected Orderbook/ Pending Orders?

As of the call dated October 28, 2021, specific details about the current order book or pending orders were not directly disclosed. Ashok Hiremath mentioned variability in Contract Manufacturing Organization (CMO) business depending on campaign-wise production with orders varying year-to-year. There was mention of around Rs.29.5 Crore of revenue deferred from Q2 to Q3 due to shipment delays. The CMO business experienced a lower contribution in H1 FY2022 but is expected to grow significantly (about 50% CAGR) over the next three years. The herbicide plant started production in August and is on t

Astec LifesciencQ2 FY22Fertilizers & Agrochemicals

Astec Lifescienc Q2 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹652.85Market Cap: ₹1.5K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Astec LifeSciences expects annualized sales growth of 15%-20% for FY2022.
Volume growth in H1 FY2022 was about 11%.
Enterprise sales value growth is targeted at 20%-25% this year, driven by 10%-15% volume growth.
CMO business is projected to grow at a compounded annual rate of 50% over the next three years.
CMO contribution is expected to rise gradually, with herbicide plant ramp-up increasing CMO capacity utilization from 30% this year to higher next year.
New product introductions: 4 CMO products and 1 enterprise product this year; 2 more enterprise products expected in FY2023.
Full utilization of the herbicide plant expected to reach 100% by the third year, currently at 30%-35% utilization.
Future growth also supported by backward integration and new fungicide plant investments.
Pricing improvements and better realizations expected to aid revenue growth despite some short-term production losses.

Margin guidance

Category 1

Astec LifeSciences targets annualized revenue growth of 15%-20% as a general guidance.
EBITDA margins expected to improve from about 22% to 24% over coming years due to higher CMO business contribution, which commands ~5% better margins than enterprise sales.
The company anticipates a 50% growth in CMO business in FY2023 as new herbicide and fungicide products ramp up.
Enterprise business volume growth expected at 10%-15% with 20%-25% value growth in the current year.
Pricing pressures on key products are easing, with improved realizations expected, particularly in H2 FY2022.
Backward integration and price hikes are expected to contribute positively to margins going forward.
New product introductions: 4 CMO products plus 1 enterprise product this year, and 2 enterprise products (triazole fungicides) expected commercially by Q4 FY2023.
Capex planned at Rs.150 crore this year, potentially increasing to support growth initiatives.

See what Astec Lifescienc management said on margin guidance — free account, 30 seconds.

Fundraise plans

The company has not explicitly mentioned any current or future fundraising plans through debt or equity in the provided transcript.
However, Ashok Hiremath indicated that recent evaluations suggest the planned investment figure (capex) may go up.
They are prepared to be more aggressive with investment plans in the future, which may imply potential future capital raising.
Currently, the company is borrowing at very low rates (4.1%) and leveraging working capital efficiently to improve profitability.
The planned capex is Rs.150 Crore for the current year and Rs.300-350 Crore over a 2-3 year window, with possibility of an upward revision.
No mention was made of any specific equity raising or debt issuance underway or planned.

Order book

As of the call dated October 28, 2021, specific details about the current order book or pending orders were not directly disclosed.
Ashok Hiremath mentioned variability in Contract Manufacturing Organization (CMO) business depending on campaign-wise production with orders varying year-to-year.
There was mention of around Rs.29.5 Crore of revenue deferred from Q2 to Q3 due to shipment delays.
The CMO business experienced a lower contribution in H1 FY2022 but is expected to grow significantly (about 50% CAGR) over the next three years.
The herbicide plant started production in August and is on track to reach 30%-35% capacity utilization in the first year, progressing towards full capacity by the third year.
The company is working on several new products (4 CMO and 1 enterprise in the current year, and 2 more enterprise products next year) which indicate order inflow in the near term.
Management expressed aspirations to increase the CMO business proportion to around 40% in coming years.

See what Astec Lifescienc management said on order book — free account, 30 seconds.

Capex plans

Yes

Capex plan for FY2022 is on track with an expected spend of Rs.150 Crore.
Investments include completion of the new herbicide facility and ongoing construction of a new fungicide plant.
A new state-of-the-art R&D center is under construction, expected to be completed by the end of FY2023; currently, additional R&D capacities have been hired externally.
Future capex estimates over a 2-3 year window are expected to be in the Rs.300-350 Crore range, with potential to increase as per recent evaluations.
The company plans to be aggressive with capital investments to expand product portfolios and capacity.
Modifications are being planned at the Mahad facility to mitigate flooding risk due to climate change effects.

Track Astec Lifescienc — get its next earnings analysis in your feed

How does Astec Lifescienc rank vs peers in Fertilizers & Agrochemicals?

Pro feature

ThisAstec Lifescienc

Rev 2Mar 1

See where Astec Lifescienc sits in Fertilizers & AgrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Astec Lifescienc rank in Fertilizers & Agrochemicals?

Compare Astec Lifescienc against every Fertilizers & Agrochemicals company (Q2 FY22) on revenue, margins and earnings-call signals.

View Fertilizers & Agrochemicals leaderboard →

What Astec Lifescienc's management said in earlier quarters

Others in Fertilizers & Agrochemicals this season

Sumitomo Chemical India Ltd (Q2 FY27)
907 crore, down 2% YoY (Q2FY26 revenue was Rs. Key investor presentation takeaways from Sumitomo Chemical India Ltd's Q2 FY27 investor presentation — and how it
Rallis India (Q2 FY27)
861 Cr. Key investor presentation takeaways from Rallis India's Q2 FY27 investor presentation — and how it ranks against sector peers.
Bhagiradha Chemicals & Industries Ltd (Q2 FY26)
140.1 crore, up 35% YoY from Rs. Key investor presentation takeaways from Bhagiradha Chemicals & Industries Ltd's Q2 FY26 investor presentation — and how it ran
Krishana Phosch. (Q2 FY26)
Trading contributes around 20%–22% of total turnover; trading volumes may vary depending on market conditions. Key concall takeaways from Krishana Phoschem…

Compare:vs Coromandel Inter vs F A C T vs UPL Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →